Clinical Trial Update: PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of AZD5363 (Capivasertib) in combination with paclitaxel for triple-negative and metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Queen Mary University of London | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED